From June 25-27, 2024, World ADC Asia 2024 will be held in Incheon, South Korea. Henlius will make a big debut at the conference and showcase its multiple ADC (Antibody Drug Conjugate) assets as well as self-developed ADC technical platform. 

As an innovative global biopharma company, Henlius has always been guided by clinical needs to build up a high-quality, affordable and differentiated pipeline to effectively meet the needs of patients and the market. Currently, its product pipeline covers more than 50 molecules with a focus on oncology, autoimmune diseases, and ophthalmic diseases. Based on its competitive edge of an integrated platform, Henlius actively explore the new target and mechanisms, continuously expanding its product portfolio in terms of therapeautic areas and modalities. As of now, the company has promoted the ADC products entered into clinical development stage, with more ADC/AXC candidates under preclinical development in Henlius’ portfolio.

During the World ADC Asia 2024, Dr. Yongqiang, Shan, General manager of Henlius Global Innovation Centerwill present as a speaker on the company’s latest innovative practice and achievements in ADC area. Meanwhile, the updated data of two potential first/best-in-class ADC products, HLX42, the novel EGFR-targeting ADC, and HLX43, the PD-L1 targeting ADC, will be published as posters at the conference. Furthermore, Henlius will showcase the company’s multiple ADC products and self-developed modular ADC toolbox and development platform Hanjugator^™ at Booth #2. We cordially invite you to visit and connect with us.